Hispanic patients were 57 percent less likely than Caucasian patients to undergo coronary artery bypass surgery (CABG) one year after successful angioplasty, a type of percutaneous coronary intervention (PCI) to open blockages in the coronary arteries.

Delaying elective coronary artery bypass graft (CABG) surgery may be a significant risk factor for post-operative death. Research published today in the open access journal BMC Health Services Research reveals that when patients received timely surgery, the risk of death was reduced by a third.

Among the many factors involved in deciding how to treat coronary artery disease, physicians must evaluate overall outcomes and the potential for complications. Some studies have found that cognitive decline and neurologic complications, such as stroke, have been associated with coronary artery bypass surgery.

Performing cardiac CTA after coronary artery bypass surgery (CABG) can reveal unsuspected and potentially significant findings beyond the heart, according to a recent study conducted by researchers at the University of Maryland School of Medicine, located in Baltimore, MD.

By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

Coronary artery bypass surgery has been the preferred treatment for patients with a blockage in the left main coronary artery, the conduit that supplies blood to about two-thirds of the heart. However, in recent years this has been challenged by stent placement in this critical artery.

Thousands of patients with heart disease may be denied the best chance of survival because of uncertainty over the most suitable treatment option, warns a cardiac surgeon in this week's BMJ.